In line with this, HER2+-BC cells and in vivo models exhibit a sustained therapeutic response to the respiratory complex I-specific inhibitor MitoTam that possesses anti-CSC properties and is currently undergoing phase I clinical trials [30, 31]. The gene discussed is ERBB2; the disease is breast cancer.